Long-Term Safety of Omalizumab in Children with Asthma and/or Chronic Spontaneous Urticaria: A 4-Year Prospective Study in Real Life

Background: Insufficient data are available on the long-term “real-life” safety profile of omalizumab in children. This study evaluated the long-term safety of omalizumab in a pediatric cohort with severe asthma or chronic spontaneous urticaria (CSU). Methods: A monocentric, prospective study evalua...

Descripción completa

Detalles Bibliográficos
Autores principales: Galletta, Francesca, Caminiti, Lucia, Lugarà, Cecilia, Foti Randazzese, Simone, Barraco, Paolo, D’Amico, Federica, Irrera, Pierangela, Crisafulli, Giuseppe, Manti, Sara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10381149/
https://www.ncbi.nlm.nih.gov/pubmed/37511681
http://dx.doi.org/10.3390/jpm13071068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10381149/
https://www.ncbi.nlm.nih.gov/pubmed/37511681
http://dx.doi.org/10.3390/jpm13071068

Ejemplares similares